Did Novartis get $150M worth of positive PhII cardio data from Akcea?
Akcea has $150 million riding on the Phase II data it just posted for a cardio drug.
The company $AKCA, a closely held affiliate of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
